Published: 10 Feb 2025
Soluble biomarkers as predictors of response to immunotherapy in Non-Small Cell Lung cancer (NSCLC)-insights from the tumor microenvironment perspective
Volume 1
Lung cancer is the major cause of mortality worldwide with non-small cell lung cancer (NSCLC) contributing to 85% of the cases. FDA approved immune checkpoint inhibitors (ICI), anti-PD-1 and anti-PD-L1 are widely used as a standard treatment. However, the response rate is limited and is observed in only 20-40% of the patients. Therefore, predictive and prognostic biomarkers are needed to help differentiate responders from non-responders, enabling a better understanding of..